Regadenoson (CV Therapeutics/Astellas).
CV Therapeutics and Astellas (formerly Fujisawa) are codeveloping the adenosine A2A receptor agonist regadenoson as a potential adjunctive intravenous pharmacological imaging agent in cardiac perfusion studies for the potential detection of coronary artery disease. Positive results from the first of two phase III clinical studies were reported in August 2005.
Department of Cardiology, University of Duisburg-Essen, Germany. holger.eggebrecht@uni-essen.de
Holger
H
Eggbrecht
Mario
M
Gössl
D058908:Adenosine A2 Receptor Agonists; D017326:Clinical Trials, Phase III as Topic; D003324:Coronary Artery Disease / Q000175:diagnosis*; D006801:Humans; D011687:Purines / Q000009:adverse effects / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics; D011720:Pyrazoles / Q000009:adverse effects / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics; D012680:Sensitivity and Specificity; D015899:Tomography, Emission-Computed, Single-Photon; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology*
D058908:Adenosine A2 Receptor Agonists; D011687:Purines; D011720:Pyrazoles; D014665:Vasodilator Agents; C430916:regadenoson